Patent · US Active

Method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response

US7361360B2 · kind B2 · utility

32Cited by
0References
18Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 26, 2006
Grant dateApr 22, 2008
Priority date
Expiry dateJul 26, 2026

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K2239/57
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to a delipidation method employing a solvent system useful for extracting lipids from cancer cells, thereby creating a modified cancer cell particle. Upon delipidation of the cancer cells, a portion of the cancer cell antigens remain intact. These exposed antigens, or epitopes, foster and promote antibody production. The resulting modified cancer cell particle, or portions of the cancer cell, initiate a positive immunogenic response when administered to an animal or human and help to treat, prevent or delay the onset of cancer. The present invention provides autologous and heterologous vaccine compositions comprising the modified cancer cell with a pharmaceutically acceptable carrier. The present invention provides method of administering these vaccines to treat, prevent or delay the onset of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.